Your browser doesn't support javascript.
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
Ying, Baoling; Scheaffer, Suzanne M; Whitener, Bradley; Liang, Chieh-Yu; Dmytrenko, Oleksandr; Mackin, Samantha; Wu, Kai; Lee, Diana; Avena, Laura E; Chong, Zhenlu; Case, James Brett; Ma, LingZhi; Kim, Thu T M; Sein, Caralyn E; Woods, Angela; Berrueta, Daniela Montes; Chang, Gwo-Yu; Stewart-Jones, Guillaume; Renzi, Isabella; Lai, Yen-Ting; Malinowski, Agata; Carfi, Andrea; Elbashir, Sayda M; Edwards, Darin K; Thackray, Larissa B; Diamond, Michael S.
  • Ying B; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Scheaffer SM; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Whitener B; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Liang CY; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Dmytrenko O; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Mackin S; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Wu K; Moderna, Inc., Cambridge, MA, USA.
  • Lee D; Moderna, Inc., Cambridge, MA, USA.
  • Avena LE; Moderna, Inc., Cambridge, MA, USA.
  • Chong Z; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Case JB; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Ma L; Moderna, Inc., Cambridge, MA, USA.
  • Kim TTM; Moderna, Inc., Cambridge, MA, USA.
  • Sein CE; Moderna, Inc., Cambridge, MA, USA.
  • Woods A; Moderna, Inc., Cambridge, MA, USA.
  • Berrueta DM; Moderna, Inc., Cambridge, MA, USA.
  • Chang GY; Moderna, Inc., Cambridge, MA, USA.
  • Stewart-Jones G; Moderna, Inc., Cambridge, MA, USA.
  • Renzi I; Moderna, Inc., Cambridge, MA, USA.
  • Lai YT; Moderna, Inc., Cambridge, MA, USA.
  • Malinowski A; Moderna, Inc., Cambridge, MA, USA.
  • Carfi A; Moderna, Inc., Cambridge, MA, USA.
  • Elbashir SM; Moderna, Inc., Cambridge, MA, USA.
  • Edwards DK; Moderna, Inc., Cambridge, MA, USA.
  • Thackray LB; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: lthackray@wustl.edu.
  • Diamond MS; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA; Andr
Cell ; 185(9): 1572-1587.e11, 2022 04 28.
Article in English | MEDLINE | ID: covidwho-1763613
ABSTRACT
The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.1., and BA.2) could jeopardize the efficacy of SARS-CoV-2 vaccines. We evaluated in mice the protective efficacy of the Moderna mRNA-1273 vaccine against BA.1 before or after boosting. Whereas two doses of mRNA-1273 vaccine induced high levels of neutralizing antibodies against historical WA1/2020 strains, lower levels against BA.1 were associated with breakthrough infection and inflammation in the lungs. A primary vaccination series with mRNA-1273.529, an Omicron-matched vaccine, potently neutralized BA.1 but inhibited historical or other SARS-CoV-2 variants less effectively. However, boosting with either mRNA-1273 or mRNA-1273.529 vaccines increased neutralizing titers and protection against BA.1 and BA.2 infection. Nonetheless, the neutralizing antibody titers were higher, and lung viral burden and cytokines were slightly lower in mice boosted with mRNA-1273.529 and challenged with BA.1. Thus, boosting with mRNA-1273 or mRNA-1273.529 enhances protection against Omicron infection with limited differences in efficacy measured.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.03.037

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.03.037